Nika Pharmaceuticals Inc.
Nika Pharmaceuticals Inc.
Share · US1513411041 (OTC)
Overview
No Price
Closing Price OTC 08.12.2025: 0,25 USD
08.12.2025 21:00
Current Prices from Nika Pharmaceuticals Inc.
ExchangeTickerCurrencyLast TradePriceDaily Change
OTC: UTC
UTC
NIKA
USD
08.12.2025 21:00
0,25 USD
0,00 USD
Company Profile for Nika Pharmaceuticals Inc. Share
Nika Pharmaceuticals, Inc., a pharmaceutical company, develops drugs for the treatment of HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes, and various other diseases. It offers dietary supplements and antiviral drugs, as well as thymus nuclear glycoprotein for the treatment of HIV. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada.
Get up to date insights from finAgent about Nika Pharmaceuticals Inc.

Company Data

Name Nika Pharmaceuticals Inc.
Company Nika Pharmaceuticals Inc.
Website https://www.nikapharmaceuticals.com
Primary Exchange OTC UTC
ISIN US1513411041
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Dimitar Slavchev Savov
Market Capitalization 286 Mio
Country United States of America
Currency USD
Employees -
Address 2269 Merrimack Valley Avenue, 89044 Henderson
IPO Date 2024-03-14

Ticker Symbols

Name Symbol
Over The Counter NIKA
More Shares
Investors who hold Nika Pharmaceuticals Inc. also have the following shares in their portfolio:
DZ BANK IS.A2205
DZ BANK IS.A2205 Bond
PT Capri Nusa Satu Properti Tbk
PT Capri Nusa Satu Properti Tbk Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025